Peter Pattison

Peter Pattison currently serves as President of Interventional Oncology at Boston Scientific since August 2019, following the acquisition of BTG plc. Pattison has held significant leadership roles in the field of oncology, including Head of Interventional Oncology at BTG plc and General Manager of TheraSphere at Nordion, focusing on commercial strategies for liver cancer treatment devices. Additional experience includes senior positions at Ricerca Biosciences and MDS Pharma Services, where responsibilities encompassed oversight of pharmacology and business development. Pattison's educational background includes a B.Sc. in Biochemistry and an MBA, both from Queen's University.